— Acasti Pharma Inc. (NASDAQ: ACST) reported Q3 2020 net loss of CAD15.7 million, or CAD0.18 per share, compared to net loss of CAD4.6 million, or CAD0.07 per share, last year.
— Loss from operating activities was CAD7.9 million compared to a loss of CAD10.7 million last year.
— R&D expenses before depreciation, amortization and stock-based compensation expenses were CAD4.2 million compared to CAD8.8 million last year.
— General and administrative expenses before stock-based compensation expenses were CAD1.6 million versus CAD0.76 million last year.
— Sales and marketing expenses before stock-based compensation expenses were CAD0.74 million compared to CAD0.13 million last year.
— Cash and cash equivalents and marketable securities totaled CAD25.7 million as of December 31, 2019.
— ACST shares gained 0.69% immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Salesforce Q3 2024 earnings increase on higher revenues, beat estimates
Customer relationship management platform Salesforce, Inc. (NYSE: CRM) reported higher earnings and revenues for the third quarter of 2024. Earnings also topped expectations. Third-quarter profit, excluding non-recurring items, increased to
AutoZone (AZO) to report Q1 2024 earnings next week. Here’s what to expect
Auto parts retailer AutoZone, Inc. (NYSE: AZO) is preparing to report first-quarter results next week, after delivering better-than-expected quarterly earnings consistently in recent years. Analysts forecast an increase in profit
Key takeaways from Hormel Foods’ (HRL) Q4 2023 earnings report
Shares of Hormel Foods Corporation (NYSE: HRL) were down over 4% on Wednesday after the company delivered fourth quarter 2023 earnings results that fell below expectations. The stock has dropped
